SCHEMBL12469460

SCHEMBL12469460

COC(=O)c1ccc(-c2nc(CS(=O)(=O)c3cccc(C)c3)c(C)o2)cc1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 8/20 0.66
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
MAPT P10636 5/20 0.57
TP53 P04637 3/20 0.55
THRB P10828 2/20 0.55
USP2 O75604 1/20 0.52
KDM4E B2RXH2 2/20 0.51
HSD17B10 Q99714 2/20 0.51
NPC1 O15118 1/20 0.51
ALDH1A1 P00352 1/20 0.51
HPGD P15428 1/20 0.51
NFKB1 P19838 1/20 0.51
RAB9A P51151 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
ATM Q13315 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12469498 0.90 POLB (0.58) POLBMEN1KMT2AMAPTTP53
SCHEMBL12469374 0.90 POLB (0.56) POLBMEN1KMT2AMAPTTP53
SCHEMBL12469078 0.89 MAPT (0.70) POLBMEN1KMT2AMAPTTP53
SCHEMBL12468828 0.88 POLB (0.69) POLBMEN1KMT2AMAPTTP53
SCHEMBL12468907 0.87 POLB (0.70) POLBMEN1KMT2AMAPTTP53
SCHEMBL12469418 0.84 POLB (0.54) POLBMEN1KMT2AMAPTTP53
SCHEMBL12469407 0.83 MEN1 (0.57) POLBMEN1KMT2AMAPTTP53
SCHEMBL12469340 0.83 POLB (0.59) POLBMEN1KMT2AMAPTTP53
SCHEMBL12469289 0.83 POLB (0.59) POLBMEN1KMT2AMAPTTP53
SCHEMBL12469523 0.83 POLB (0.59) POLBMEN1KMT2AMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296732-B2 Substituted benzamides and their uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2016-03-29 US disclosed
US-20150329503-A1 SUBSTITUTED BENZAMIDES AND THEIR USES UNIV LELAND STANFORD JUNIOR (US) 2015-11-19 US disclosed
US-9085570-B2 Substituted benzamides and their uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-07-21 US disclosed
US-20150072976-A1 SUBSTITUTED BENZAMIDES AND THEIR USES ARAVIVE BIOLOGICS, INC. 2015-03-12 US disclosed
EP-2838534-A2 SUBSTITUTED BENZAMIDES AND THEIR USES The Board of Trustees of The Leland Stanford Junior University (US) 2015-02-25 EP disclosed
US-20140024649-A1 Substituted Benzamides and Their Uses AUCKLAND UNISERVICES LIMITED (NZ) 2014-01-23 US disclosed
WO-2013155338-A2 SUBSTITUTED BENZAMIDES AND THEIR USES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2013-10-17 WO disclosed
EP-2627324-A2 SUBSTITUTED BENZAMIDES AND THEIR USES The Board of Trustees of The Leland Stanford Junior University (US) 2013-08-21 EP disclosed
WO-2012051117-A2 SUBSTITUTED BENZAMIDES AND THEIR USES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2012-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329503-A1 SUBSTITUTED BENZAMIDES AND THEIR USES NISCH, BTD, NAAA POLB 970/4885MEN1 2797/4885KMT2A 459/4885
US-20140024649-A1 Substituted Benzamides and Their Uses NISCH, BTD, NAAA POLB 970/4885MEN1 2797/4885KMT2A 459/4885
US-20150072976-A1 SUBSTITUTED BENZAMIDES AND THEIR USES NISCH, BTD, NAAA POLB 970/4885MEN1 2797/4885KMT2A 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.